Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support

Related Articles

Malignancy in patients with haemophilia: a review of the literature
Haemophilia, 11/16/09    Relevance Score: 89%%

Co-morbidities and quality of life in elderly persons with haemophilia
British Journal of Haematology, 12/12/09    Relevance Score: 87%%

Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa
Haemophilia, 11/25/09    Relevance Score: 85%%

The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery
Haemophilia, 11/25/09    Relevance Score: 85%%

Upper gastrointestinal bleeding in children with haemophilia: a clinical significance of Helicobacter pylori infection
Haemophilia, 11/09/09    Relevance Score: 85%%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address